DNLI News and Press, Denali Therapeutics Inc. From 01/25/23

Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosis Denali to receive a milestone payment of $25 million from Sanofi for Phase 2 clinical trial initiation Development of RIPK1 inhibitor program continues in a broad...

Summary Denali Therapeutics Inc. has major partnerships and an active set of programs. They are flush with cash. Denali Therapeutics needs to show us human patient data. I have been covering Denali Therapeutics Inc. ( DNLI ) for a few years now. Denali has three th...

Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinson’s disease Further validation and expansion of Transport Vehicle (TV) technology, including multiple interim clinical data readouts, submission of IND for additional ETV pr...

DNL343 demonstrated extensive blood-brain barrier penetration and robustly inhibited the integrated stress response pathway implicated in ALS Once-daily oral dosing with DNL343 for 28 days was generally well tolerated in participants with ALS The design phase for entry of DNL343 into a ...

Denali Therapeutics press release ( NASDAQ: DNLI ): Q3 GAAP EPS of -$0.84 misses by $0.06 . Collaboration Revenue of $3.56M (-32.7% Y/Y). Cash, cash equivalents, and marketable securities were approximately $1.11 billion as of September 30, 2022. For further ...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial r...

Denali Therapeutics (NASDAQ: DNLI) , a biopharmaceutical company that focuses on therapies to treat neurodegenerative disorders, had a bit of a seesaw day on Wednesday. The stock rose as much as 12.4% before finishing the day up 6.6% over Tuesday. It closed on Tuesday at $28.96, the...

BTIG has upgraded Denali Therapeutics to buy from neutral after the biotech showed that a second candidate was able to cross the blood-brain barrier in an early-stage study. The firm has a $38 price target (~31% upside based on Tuesday's close). Shares are up ~8% in Wednes...

Interim results from Part A in healthy volunteers demonstrated dose-dependent increases in CSF progranulin levels, consistent with robust brain delivery of DNL593 Single doses of DNL593 were generally well tolerated Data support progression to enrolling participants with FTD-GRN...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...